Peptide Guides
KLOW Peptide Blend: GLOW Plus KPV, and What That Addition Changes
KLOW is GLOW with a fourth component. Understanding what KPV adds — and what a four-peptide fixed ratio costs you — is the whole question.
Peptide Library Editorial · March 31, 2026 · Updated August 30, 2026 · 3 min read

KLOW is the GLOW blend with a fourth peptide added: KPV. The common configuration is 80 mg total — 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV.
Comparing the two is straightforward because they differ by exactly one component. Everything else about them, including the awkward arithmetic, is the same.
Not an approved product. None of the four components is an approved drug, and the combination has never been studied as such. Sold for laboratory research only; nothing here is dosing guidance.
GLOW vs KLOW
Component | GLOW | KLOW |
|---|---|---|
GHK-Cu | 50 mg | 50 mg |
BPC-157 | 10 mg | 10 mg |
TB-500 | 10 mg | 10 mg |
KPV | — | 10 mg |
Total | 70 mg | 80 mg |
See the GLOW guide for the three shared components. What follows concerns the addition.
What KPV adds
KPV is a tripeptide — lysine-proline-valine — corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone. Unlike the parent hormone it carries no pigmentation activity; the research interest is in anti-inflammatory signalling.
That is a different proposition from the other three. GHK-Cu, BPC-157 and TB-500 are all discussed in terms of tissue repair. KPV is discussed in terms of damping inflammation — which is why adding it is framed as complementary rather than redundant. The KPV guide covers the compound on its own.
Note the reasoning being made here: four mechanisms are better than three. That is a plausible hypothesis and nothing more — no controlled study has compared KLOW against GLOW, or either against any single component.
The vial math
Four calculations, one diluent volume. For an 80 mg vial reconstituted with 5 mL:
Component | Mass | Concentration | 10 units delivers |
|---|---|---|---|
GHK-Cu | 50 mg | 10 mg/mL | 1 mg |
BPC-157 | 10 mg | 2 mg/mL | 200 mcg |
TB-500 | 10 mg | 2 mg/mL | 200 mcg |
KPV | 10 mg | 2 mg/mL | 200 mcg |
The GHK-Cu component drives everything. At 50 mg it is five times the mass of any other component. Dissolving it at a workable concentration means a lot of diluent, and a lot of diluent means a lot of solution to use inside the 28-day window. That constraint is the practical problem with these blends, and it is rarely mentioned on the product page.
The fixed-ratio constraint tightens with every component added. With four peptides locked together, a change to any one of them is a change to all four. The peptide calculator handles per-component concentrations for blends.
The attribution problem
This is the argument against blends that gets stronger the more components there are. With four peptides in one draw, any effect — good or bad — cannot be attributed to any of them.
For a research context that is a serious limitation, because the entire point of a controlled observation is knowing what changed. Separate vials cost more and take more work; they are also the only version of this that produces interpretable information.
Storage
Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.
Frequently asked questions
Is KLOW better than GLOW?
No study has compared them. KLOW contains one additional component with a different proposed mechanism, which is an argument, not evidence.
Why is GHK-Cu so much larger than the rest?
Because it is discussed at milligram scale where the others are discussed at microgram scale. The ratio reflects the different amounts each component is typically used at, not their relative importance.
Can I get the components separately?
Yes, and it is the only way to vary them independently or to attribute an effect. Compare on price per mg rather than on the headline vial price.
Research and educational use only. Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.
Sources
- 1. KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling — Tissue and Cell (2026) Source PubMed
- 2. The Regenerative Potential of GHK-Cu in Aesthetic Medicine — Aesthetic Surgery Journal (2026) Source PubMed
- 3. Tendon, Ligament, and Muscle Injury Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157 — A Review — Pharmaceuticals (Basel) (2026) Source PubMed
Author
Peptide Library Editorial
Editorial content from Peptide Library. Research and educational use only. Not medical advice.
Related articles
Related peptides
Related tools
Research smarter with Peptide Library.
Compare peptides, review vendor data, and use research calculators in one place.
Explore the LibraryResearch and educational use only. Not medical advice. Peptide Library does not sell peptides.